These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

268 related items for PubMed ID: 17968971

  • 1. Why insulin sensitizers but not secretagogues should be retained when initiating insulin in type 2 diabetes.
    Raskin P.
    Diabetes Metab Res Rev; 2008; 24(1):3-13. PubMed ID: 17968971
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Therapeutic approach of type 2 diabetes mellitus with GLP-1 based therapies.
    Penfornis A, Borot S, Raccah D.
    Diabetes Metab; 2008 Feb; 34 Suppl 2():S78-90. PubMed ID: 18640590
    [Abstract] [Full Text] [Related]

  • 5. DPP-4 inhibitors and GLP-1 analogues: for whom? Which place for incretins in the management of type 2 diabetic patients?
    Halimi S.
    Diabetes Metab; 2008 Feb; 34 Suppl 2():S91-5. PubMed ID: 18640591
    [Abstract] [Full Text] [Related]

  • 6. Insulin in the early management of diabetic complications.
    Miles JM.
    J Assoc Physicians India; 2003 May; 51():501-5. PubMed ID: 12974435
    [Abstract] [Full Text] [Related]

  • 7. Insulin initiation in Type 2 diabetes.
    Page S.
    Diabet Med; 2005 Sep; 22 Suppl 4():2-5. PubMed ID: 16109011
    [No Abstract] [Full Text] [Related]

  • 8. Insulin as a first-line therapy in type 2 diabetes: should the use of sulfonylureas be halted?
    Standl E, Schnell O.
    Diabetes Care; 2008 Feb; 31 Suppl 2():S136-9. PubMed ID: 18227474
    [No Abstract] [Full Text] [Related]

  • 9. Guideline-conformity of initiation with oral hypoglycemic treatment for patients with newly therapy-dependent type 2 diabetes mellitus in Austria.
    Winkelmayer WC, Stedman MR, Pogantsch M, Wieninger P, Bucsics A, Asslaber M, Bauer R, Burkhardt T, Schautzer A, Brookhart MA, Pharmacoeconomics Advisory Council of the Main Association of Austrian Sickness Funds.
    Pharmacoepidemiol Drug Saf; 2011 Jan; 20(1):57-65. PubMed ID: 21182153
    [Abstract] [Full Text] [Related]

  • 10. Treatment of type 2 diabetes with combined therapy: what are the pros and cons?
    Massi-Benedetti M, Orsini-Federici M.
    Diabetes Care; 2008 Feb; 31 Suppl 2():S131-5. PubMed ID: 18227473
    [Abstract] [Full Text] [Related]

  • 11. [Triple oral therapy in type 2 diabetes].
    Scheen AJ.
    Rev Med Suisse; 2005 Aug 24; 1(30):1942, 1944-6, 1948. PubMed ID: 16200937
    [Abstract] [Full Text] [Related]

  • 12. Role of insulin secretagogues and insulin sensitizing agents in the prevention of cardiovascular disease in patients who have diabetes.
    Jawa AA, Fonseca VA.
    Cardiol Clin; 2005 May 24; 23(2):119-38. PubMed ID: 15694742
    [Abstract] [Full Text] [Related]

  • 13. Race, ethnicity, and use of thiazolidinediones among US adults with diabetes.
    Aquilante CL, Zhang W, McCollum M.
    Curr Med Res Opin; 2007 Mar 24; 23(3):489-94. PubMed ID: 17355730
    [Abstract] [Full Text] [Related]

  • 14. The risk of coronary heart disease in type 2 diabetic patients exposed to thiazolidinediones compared to metformin and sulfonylurea therapy.
    Johannes CB, Koro CE, Quinn SG, Cutone JA, Seeger JD.
    Pharmacoepidemiol Drug Saf; 2007 May 24; 16(5):504-12. PubMed ID: 17245800
    [Abstract] [Full Text] [Related]

  • 15. Homeostasis model assessment (HOMA) as surrogate insulinization criteria in patients with type 2 diabetes.
    Bermúdez V, Cano R, Cano C, Bermúdez F, Leal E, Acosta K, Mengual E, Arraiz N, Briceño C, Gómez J, Bustamante M, Aparicio D, Cabrera M, Valdelamar L, Rodriguez M, Manuel V, Hernández R.
    Am J Ther; 2008 May 24; 15(4):409-16. PubMed ID: 18645347
    [Abstract] [Full Text] [Related]

  • 16. Progression to insulin for patients with diabetes mellitus on dual oral antidiabetic therapy using the US Department of Defense Database.
    Rascati K, Richards K, Lopez D, Cheng LI, Wilson J.
    Diabetes Obes Metab; 2013 Oct 24; 15(10):901-5. PubMed ID: 23531154
    [Abstract] [Full Text] [Related]

  • 17. Optimizing antidiabetic treatment options for patients with type 2 diabetes mellitus and cardiovascular comorbidities.
    Malesker MA.
    Pharmacotherapy; 2008 Feb 24; 28(2):193-206. PubMed ID: 18225965
    [Abstract] [Full Text] [Related]

  • 18. Metformin: old wine in new bottle--evolving technology and therapy in diabetes.
    Joshi SR.
    J Assoc Physicians India; 2005 Nov 24; 53():963-72. PubMed ID: 16515237
    [Abstract] [Full Text] [Related]

  • 19. Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study.
    Derosa G, Maffioli P, Salvadeo SA, Ferrari I, Gravina A, Mereu R, Palumbo I, D'Angelo A, Cicero AF.
    Metabolism; 2009 Aug 24; 58(8):1059-66. PubMed ID: 19394976
    [Abstract] [Full Text] [Related]

  • 20. Oral hypoglycemic agents in type II diabetes mellitus.
    Lubbos H, Miller JL, Rose LI.
    Am Fam Physician; 1995 Nov 15; 52(7):2075-8. PubMed ID: 7484707
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.